Trending

Filed under: News | Misc

 

FDA Panel Rejects Medicines Company's Heart Drug

Feb 12 2014, 6:43pm CST | by

1 Updates
FDA Panel Rejects Medicines Company's Heart Drug
 
 

YouTube Videos Comments

Full Story

FDA Panel Rejects Medicines Company's Heart Drug

The FDA’s Cardiovascular and Renal Drugs Advisory Committee today recommended against the approval of cangrelor, the investigational new antiplatelet drug from the Medicines Company. In a 7-2 vote the panel first rejected an indication  for the reduction of thrombotic cardiovascular events including stent thrombosis in patients undergoing PCI.

The panel also voted unanimously to reject a second indication, for the maintenance of antiplatelet therapy in patients with acute coronary syndromes or patients with stents who have discontinued antiplatelet therapy because they are awaiting surgery and are at high risk for thrombotic events. FDA reviewers, who had delivered mixed opinions for the first indication, had recommended a complete response letter for the second indication, since the company had failed to perform a trial showing clinical benefit for the indication.

Throughout the day panel members wrestled with problems with the pivotal CHAMPION PHOENIX trial, which attempted to remedy the deficiencies of two earlier negative trials. Although most panel members agreed that PHOENIX showed a benefit compared to the clopidogrel control group, the benefit appeared small and the committee was concerned that cangrelor may have received an unfair advantage because in the control group clopidogrel was not used ideally, since many  did not receive preloaded high-dose clopidogrel. An additional concern was that most of the difference between the groups was due to a reduction in periprocedural MIs. Panelists once again raised the question of the clinical relevance of this finding. Finally, the higher risk of bleeding with clopidogrel appeared to largely offset the observed benefits.

Panel member Milton Packer, who voted against approval, said that he wanted to vote yes and that he thought an antiplatelet agent with rapid on/off properties might well prove useful. But, he said, the sponsor had not demonstrated that cangrelor was superior to full dose clopidogrel.

Source: Forbes

 

You Might Also Like

Updates


Sponsored Update


Advertisement


More From the Web

Shopping Deals

 
 
 

<a href="/latest_stories/all/all/31" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

 

Comments

blog comments powered by Disqus

Latest stories

Samsung Launches Brand New Design Website
Samsung Launches Brand New Design Website
Samsung is in the midst of fighting a legal battle over copyright issues with Apple. And is it a mere coincidence that it has launched a brand new design website in the present predicament in which it finds itself?
 
 
Samsung outs colorful ad for Galaxy S5 and Samsung Gear
Samsung outs colorful ad for Galaxy S5 and Samsung Gear
The new ad by Samsung focuses on the new Galaxy S5 and Galaxy Gear features
 
 
Samsung to Launch Tizen Phones in Q2 and Android Wear Smartwatch Later
Samsung to Launch Tizen Phones in Q2 and Android Wear Smartwatch Later
Samsung Electronics is up to its good old tinkering ways once again. The company will be introducing at least two smartphones running on its own Tizen operating system in Q2 and an Android Wear smartwatch later this year.
 
 
Microsoft launches cheaper Office 365 Personal subscription
Microsoft launches cheaper Office 365 Personal subscription
Microsoft has come up with a cheaper subscription plan for Office 365 productivity suite
 
 
 

The Hottest Photos of Victoria's Secret Fashion Show 2013